✦ LIBER ✦

A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer

✍ Scribed by Masaru Izuo; Minoru Yoshida; Takeshi Tominaga; Osahiko Abe; Koji Enomoto; Yasuo Nomura; Kanji Kubo; Osamu Takatani

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 356 KB
Volume: 56
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19851201)56:11<2576::aid-cncr2820561107>3.0.co;2-i

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose medroxyprogesterone acetate in

High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen

✍ Reinhard Becher; Antonius A. Miller; Klaus Höffken; Udo Gerhold; Herbert Hirche; 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

Anastrozole versus megestrol acetate in

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials

✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace